Shady, N., Sallam, H. (2022). The Clinical Outcome of Intravenous Single Bolus 0.5gm of Tranexamic Acid for Reducing Blood Loss Following an Elective Cesarean Delivery: A Randomized Controlled Trial. Suez Canal University Medical Journal, 25(1), 125-134. doi: 10.21608/scumj.2022.240848
Nahla W. Shady; Hany F. Sallam. "The Clinical Outcome of Intravenous Single Bolus 0.5gm of Tranexamic Acid for Reducing Blood Loss Following an Elective Cesarean Delivery: A Randomized Controlled Trial". Suez Canal University Medical Journal, 25, 1, 2022, 125-134. doi: 10.21608/scumj.2022.240848
Shady, N., Sallam, H. (2022). 'The Clinical Outcome of Intravenous Single Bolus 0.5gm of Tranexamic Acid for Reducing Blood Loss Following an Elective Cesarean Delivery: A Randomized Controlled Trial', Suez Canal University Medical Journal, 25(1), pp. 125-134. doi: 10.21608/scumj.2022.240848
Shady, N., Sallam, H. The Clinical Outcome of Intravenous Single Bolus 0.5gm of Tranexamic Acid for Reducing Blood Loss Following an Elective Cesarean Delivery: A Randomized Controlled Trial. Suez Canal University Medical Journal, 2022; 25(1): 125-134. doi: 10.21608/scumj.2022.240848
The Clinical Outcome of Intravenous Single Bolus 0.5gm of Tranexamic Acid for Reducing Blood Loss Following an Elective Cesarean Delivery: A Randomized Controlled Trial
Department of Obstetrics and Gynecology, Aswan Faculty of Medicine, Aswan University, Aswan, Egypt
Abstract
Objective: To assess the effectiveness and safety ofintravenous single bolus 0.5 gm Tranexamic acid ( TA ), compared with 1 gm TA and placebo in reducing blood loss during and after cesarean delivery in women who have at least one risk factor for postpartum hemorrhage(PPH). Subjects and Methods: A randomized clinical trial, at a tertiary University Hospital between November 1, 2018, and July 30, 2020, (: NCT03710330) was conducted on 360 pregnant women at term (37–40 weeks) gestation scheduled for elective cesarean delivery, who were assigned to either 0.5 gm,1 gm, or, placebo(saline). The main outcome measures were blood loss at and 6 hours after cesarean delivery, the need for any additional oxytocic drugs, and TA-related side effects. Results: The mean overall blood loss was (609.33 ± 211.5), intraoperative was (465.58 ± 191) and post-operative was (143.75 ± 33.33) in group 2 compared with (829.7 ± 293.3), (665.5 ± 272.2), (165.83 ± 36.59) in group 1 respectively and (751 ± 208.09), (587.75 ± 190.6), (164.08 ± 32.53) in group 3 respectively , so group 2 showed great significant reduction in overall estimated blood loss either intraoperative or post-operative compared with group 1 ,( p = 0.0001,0.0001,0.0001) and group 3, (p= 0.0001,0.0001,0.0001). Conclusion: Both 0.5 gm and 1 gm TA may be more effective than a placebo in reducing total blood loss during and after CD, but 1gm TA may be more effective than 0,5 gm TA in reducing blood loss during and after CD in women who have a minimum of one risk factor for postpartum hemorrhage, for instance, twin pregnancy, macrosomia, and history of PPH, etc.
View on SCiNiTO
Top